- Home
- TOPP vs BNR Comparison
TOPP vs BNR Comparison
Compare TOPP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- BNR
- Stock Information
- Founded
- TOPP 2014
- BNR 2014
- Country
- TOPP United States
- BNR China
- Employees
- TOPP N/A
- BNR N/A
- Industry
- TOPP
- BNR Medical Specialities
- Sector
- TOPP
- BNR Health Care
- Exchange
- TOPP NYSE
- BNR Nasdaq
- Market Cap
- TOPP 26.6M
- BNR 29.1M
- IPO Year
- TOPP 2025
- BNR 2020
- Fundamental
- Price
- TOPP $1.73
- BNR $3.70
- Analyst Decision
- TOPP
- BNR
- Analyst Count
- TOPP 0
- BNR 0
- Target Price
- TOPP N/A
- BNR N/A
- AVG Volume (30 Days)
- TOPP 7.9K
- BNR 36.5K
- Earning Date
- TOPP 08-11-2025
- BNR 08-21-2025
- Dividend Yield
- TOPP N/A
- BNR N/A
- EPS Growth
- TOPP N/A
- BNR N/A
- EPS
- TOPP N/A
- BNR N/A
- Revenue
- TOPP $16,117,227.00
- BNR $72,112,038.00
- Revenue This Year
- TOPP N/A
- BNR $136.32
- Revenue Next Year
- TOPP N/A
- BNR N/A
- P/E Ratio
- TOPP N/A
- BNR N/A
- Revenue Growth
- TOPP 0.44
- BNR 0.53
- 52 Week Low
- TOPP $0.97
- BNR $2.18
- 52 Week High
- TOPP $4.50
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- BNR 59.32
- Support Level
- TOPP N/A
- BNR $3.06
- Resistance Level
- TOPP N/A
- BNR $3.50
- Average True Range (ATR)
- TOPP 0.00
- BNR 0.25
- MACD
- TOPP 0.00
- BNR 0.01
- Stochastic Oscillator
- TOPP 0.00
- BNR 69.57
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.